Livzon Pharmaceutical Group Inc. (SHE:000513)

Market Cap	31.80B
Revenue (ttm)	11.80B
Net Income (ttm)	2.17B
Shares Out	889.24M
EPS (ttm)	2.39
PE Ratio	15.98
Forward PE	15.29
Dividend	1.10 (2.88%)
Ex-Dividend Date	Jun 13, 2025

Volume	5,890,885
Average Volume	9,121,351
Open	38.43
Previous Close	38.66
Day's Range	37.79 - 38.50
52-Week Range	32.94 - 44.87
Beta	0.27
RSI	37.44
Earnings Date	Oct 24, 2025

About SHE:000513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers Ilaprazole enteric-coated tablets and ilaprazole sodium for injection a series of bismuth potassium citrate products for gastrointestinal field; leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for assisted reproduction field; fluvoxamine maleate and perospirone hydrochloride tablets for psychiatric...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000513

Financial Performance

In 2024, SHE:000513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.